RVL Pharmaceuticals plc (RVLPQ)

Market Cap	111.00
Revenue (ttm)	36.92M
Net Income (ttm)	-68.27M
Shares Out	111.41M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Average Volume	46,618
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	41.22
RSI	42.88
Earnings Date	Aug 14, 2025

About RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and chan...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brian Markison
• Employees: 125
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVLPQ

Financial Performance

In 2022, RVL Pharmaceuticals's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.